Searched for
VIR BIOTECHNOLOGY
India’s realty equity inflows hit record $30.7 billion between 2024-Q1 2026Between 2024 and early 2026, India’s real estate landscape witnessed an astonishing influx of over $30 billion in equity capital, showcasin...- Next Gurgaon in Noida? UP planning big aerotropolis near Jewar International AirportThe aerotropolis project aims to create a thriving hub for residential and industrial purposes, centered around the airport. The aerotropol...
- Pfizer's $11.6 bn Biohaven buy could spark more biotech dealsThe deal, announced on Tuesday, is the biggest in the sector so far this year and ends a dearth of large acquisitions, which along with cli...
- GSK-Vir therapy works against Omicron sub-variant, data suggestsBased on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain...
- GSK to increase Covid drug capacity, but no plans for India yetThe company didn't specify any timelines on when the drug will be available in India, or whether it has initiated any discussions with the ...
- J&J, Sinopharm, Sputnik V COVID-19 shots less effective against Omicron -studyVaccines from Moderna, AstraZeneca, Pfizer and partner BioNTech retained activity against Omicron, but the antibody response was greatly re...
- Wall Street closes higher with Nasdaq boosted by tech rallyThe Dow Jones Industrial Average rose 492.4 points, or 1.4%, to 35,719.43, the S&P 500 gained 95.08 points, or 2.07%, to 4,686.75 and the N...
- Oil edge lower as investors try to assess Omicron's full impactBrent crude futures dropped 25 cents, or 0.3%, to $75.19 a barrel at 0129 GMT, after settling 3.2% higher on Tuesday. U.S. West Texas Inter...
- Aussie buoyant, dollar listless as Omicron optimism lifts risk assetsThe Australian dollar hit its strongest level in a week on Wednesday amid a pick-up in risk appetite on signs Omicron may be less severe th...
- Omicron more transmissible than Delta: UK PM Boris Johnson to ministersJohnson's official Number 10 Downing Street spokesperson told reporters in an account of the Cabinet meeting that Johnson reiterated it was...
- New data shows GSK-Vir drug works against all Omicron mutationsThe data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all...
- GSK says antibody drug 'Sotrovimab' works against OmicronUK's Medicines and Healthcare products Regulatory Agency has approved sotrovimab, a Covid-19 treatment which has been developed by GSK and ...
- AstraZeneca says antibody treatment failed in preventing COVID-19 in exposed patientsThe company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...
- India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktailRegeneron and Roche's antibody cocktail has also received emergency use approval in India, and will be distributed by drugmaker Cipla. The ...
- GSK, Vir Biotech to expand COVID-19 research partnership for other diseasesAs a part of the deal to research and develop monoclonal antibody treatments for influenza and other respiratory illnesses, GSK will make a...
- View: Why vaccines alone would not be enough to beat Covid-19Vaccines can’t change the course of the pandemic overnight, and may not be able to entirely stop the spread of the virus. It will take mont...
- GSK to widen COVID-19 antibody treatment trial after safety clearanceThe long-acting single injection will be tested on recently diagnosed high-risk cases for its ability to prevent hospitalisation, typically...
- Lilly says antibody drug cuts COVID-19 hospitalization, may seek emergency use nodOf the total 302 patients treated with the Lilly drug, five or 1.7%, had to be hospitalized or required an emergency room visit. That compa...
- Next best thing to vaccine: Companies testing antibody drugs to treat, prevent Covid-19Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by trickin...
- Bull run for private technology funding market coming to an end: Softbank's Deep NisharNishar said the debacle at WeWork, which SoftBank bailed out with a $9.5 billion cash injection, was an extreme case of dissonance between ...
Load More
